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Abstract
The presence of circulating tumor cells (CTCs) in the blood of cancer patients may guide the use of therapy.
We investigated how to evaluate a reduction in the number of CTCs after administration of therapy. CTCs were
enumerated with the CellSearch system in 111 metastatic breast and 185 metastatic prostate cancer patients
before start of a new line of chemotherapy and after initiation of therapy. Different means to express changes
in CTC counts were evaluated with respect to overall survival (OS). A static CTC cutoff is the best method to
determine whether a therapy is effective. This is exemplified by the highest Cox hazard ratio of 2.1 for OS; three
methods to express relative differences performed worse. A lookup table is provided from which the significance
of a change in CTCs can be derived. The aim of therapy should be the elimination of all CTCs. A period of 10 to
12 weeks of therapy is needed to reach the treatment effect on CTCs.
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Introduction
The presence of circulating tumor cells (CTCs) has been associated
with poor survival in melanoma, breast, colorectal, prostate, gastric,
small and non–small cell lung cancer [1–7]. The association between
the presence of CTCs and poor prognosis holds true before and at
various time intervals after initiation of therapy [3,4,8]. Transition
from unfavorable (≥5 CTCs/7.5 ml of blood) to favorable CTCs
(<5 CTCs/7.5 ml of blood) improves survival and, as such, can be
used as a predictive factor for treatment response [2–4,8]. Conver-
sion to favorable or unfavorable CTCs may be a better and earlier
indicator of therapy response compared to imaging [3,9,10]. Al-
though conversion to no detectable CTCs most likely gives the best
outcome, the time needed to assure whether or not this target is
reached under the current treatment regimen is unknown. Accurate
measurement of a decline in CTCs is hampered by the low frequency
of CTCs in most patients with metastatic disease [11]. Not only
the continuous relationship between CTC concentration and sur-
vival but also the Poisson sampling error suggests that dichotomiza-
tion may not be the best approach to detect effective chemotherapy
[12–14].
A change in therapy is typically initiated upon establishment of
the ineffectiveness of the current therapy. The goal of this study
was to investigate how to define therapy success using the number
of CTCs. To address this question, we estimated the prognostic
power of various methods to express a change in the CTC number.
Materials and Methods
Patient Data
For this study, we used stored images of CTC measurements from
patients before initiation of a new cycle of cytotoxic chemotherapy
(baseline) and at several follow-up time points in a 13-week period
after initiation of therapy. Samples from patients enrolled into the
IMMC-01 metastatic breast cancer [2] and IMMC-38 metastatic
prostate cancer [4] studies were used. This study included 111 base-
line samples and 265 follow-up samples from 111 metastatic breast
cancer patients and 185 baseline and 425 follow-up samples from
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185 metastatic prostate cancer patients. Two hundred five samples from
healthy controls were also available [11,15]. All patients provided written
informed consent. The institutional review boards at each participat-
ing center approved the respective study protocols. Table W1 shows a
summary of the patient characteristics.
CTC Enumeration
The CellSearch system (Veridex LLC, Raritan, NJ) was used for
enumeration of CTCs. The system consists of a sample preparation sys-
tem and a sample analysis system [11]. Epithelial (EpCAM-positive)
cells are immunomagnetically enriched from 7.5 ml of blood. The
enriched sample is stained with fluorescent antibody conjugates to de-
tect the presence of cytokeratins (CK) 8, 18, and 19 and the absence
of CD45. The presence of a nucleus is detected with the nuclear dye
4′,6-diamidino-2-phenylindole (DAPI). The sample is imaged by the
CellTracks Analyzer II that records digital images for four different
fluorescent dyes, using a 10×/0.45 numerical aperture (NA) objective.
To arrive at a final CTC count, objects that are CK+DAPI+ are selected
by an algorithm and presented in a gallery to a trained reviewer. The
reviewer scores events as CTCs when they are CD45 negative, larger
than 4 μm, and have a cell-like morphology.
Poisson Model for Reduction in CTC Count
The three major sources of variation in CTC counting are [13] 1)
the Poisson distributed sampling error of the number of CTCs in a
sample, 2) the variability in enrichment efficiency, and 3) the intra-
reader and inter-reader variabilities. With 80 ± 15% assay efficiency
[13], the sampling error is dominant up to 44 CTCs and only this
error will be taken into account. When taking a sample from a large
volume with a concentration of λ objects per sample volume, the
probability that we find k objects in that sample is given by the fol-
lowing Poisson distribution:
P X = kð Þ = e
−λλk
k!
f or k = 0; 1; 2… ð1Þ
The probability that a pair of successive measurements represents
a reduction in the true mean number of CTCs was determined in
Matlab 2009a (Mathworks, Natick, MA). For two measurements
k1 and k2, the probability was derived that λ2 is smaller than λ1,
as represented in the following equation:
Pðλ2 < λ1Þ =
Z ∞
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λ1≥λ2
PðX = k1Þdλ1
 
dλ2; ð2Þ
in which k1 and λ1 represent the first and k2 and λ2 represent the
second CTC measurement. This equation compares two distribu-
tions of underlying true means λ derived from the measured k’s. First,
for the two k’s, the probability is simulated that it originates from
a certain mean λ; this distribution is normalized to 1. Second, for
every λ from k2, the probability that it is lower than the λ’s from k1
is determined. This total is summed to determine the total probability
that k2 came from a lower true mean than k1. Using Equation 2,
we can determine the confidence for a CTC reduction given any
pair of measurements. For each combination of baseline and follow-up
measurement ranging from 0 to 50, the confidence for a true reduction
was calculated.
CTC Reduction Criteria
The ability to predict favorable outcome was tested using several
criteria to express CTC reduction. Tested criteria were given as follows:
1. Conversion to favorable group (from ≥x to <x CTCs): setting
a static cutoff.
2. Reduction confidence larger than x%: according to Equation 2.
3. Measurement 2 is x smaller than measurement 1: an absolute
reduction cutoff.
4. Measurement 2 is x times smaller than measurement 1: a propor-
tional reduction cutoff.
The parameter x was determined for each reduction criterion as
described in Statistical Analysis section. Only patients with ≥5 CTCs
at baseline were used for this analysis (N = 164).
Statistical Analysis
For each criterion, the hazard ratio (HR) was determined. To deter-
mine how well different criteria stratify patients into two groups, the
relative size of the two groups resulting from each criterion must be
balanced. To achieve this, the x in criteria 1 to 4 was set such that
the percentages of patients in the favorable and unfavorable groups were
similar to the clinically validated CTC cutoff in criterion 1. The per-
centage of patients who remained unfavorable was 59% using criterion
1 for x = 5 CTCs. Thus, for each criterion, the variable x was set to
approximate the unfavorable group at 59%. Survival curves were com-
pared with the use of log-rank testing. Overall survival (OS) was mea-
sured from the time of blood draw to time of death from any cause.
Results
OS as a Function of CTC Number
CTCs were enumerated with the CellSearch system in 296 blood
samples at the first follow-up after initiation of a new line of therapy
in 296 metastatic patients (111 breast and 185 prostate). Patients were
divided into four groups using the CTC count per 7.5 ml of whole
blood [0 CTC (N = 123), 1 to 4 CTCs (N = 67), 5 to 24 CTCs
(N = 55), and ≥25 CTCs (N = 51)]. Figure 1 shows the Kaplan-
Meier plot; log-rank P was less than .05 between any two lines.
Changes in the CTC Number and OS
Metastatic breast and prostate cancer patients were separated
into 164 (55%) patients with unfavorable CTCs (≥5 CTCs) and
132 (45%) with favorable CTCs (<5 CTCs) at baseline. To illustrate
the relationship between changes in CTC count and OS, patients were
further subdivided into groups that survived 1 to 6, 6 to 12, 12 to 24,
and 24 to 36 months. From the 296 patients, 690 blood samples
were taken in 4- to 6-week intervals after therapy initiation. Smoothed
splines were used to show the relationship between the median num-
ber of CTCs and time for the different survival groups. Figure 2, A
and B, shows patients with unfavorable baseline CTCs and favor-
able baseline CTCs, respectively. The patients who survived only 1
to 6 months showed a relative CTC increase of three-fold to four-fold
for both patients with unfavorable and patients with favorable base-
line CTCs. For patients surviving 6 to 12 months with unfavorable
baseline CTCs, a trend of slight CTC decrease followed by an increase
was observed and CTCs steadily increased in patients with a favorable
baseline. For patients surviving 12 to 24 and 24 to 36 months, CTCs
decreased to 0 CTC after 10 to 12 weeks of therapy.
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True CTC Changes Determined Using Poisson Model
CTC measurements on a patient at successive times may show a
decline in CTCs. For low CTC number, this decline may reflect a
true decline in the number of CTCs in the patient’s blood, but it
may also be due to the Poisson sampling error. A lookup table shown
in Figure 3, which can be used as a reference to determine confidence
for a true CTC reduction in the range of 0 to 50 CTCs, was created.
For example, in case the baseline measurement is seven CTCs, de-
tecting zero to one CTC at follow-up provides a CTC reduction
confidence of >95% (Figure 3, lower arrow), whereas for a CTC
follow-up count of five to nine this confidence reduces to 25 to
75%. A follow-up measurement of 10 to 14 CTCs gives confidence
of 5 to 25%, and for a follow up count above 14 CTCs, confidence of
reduction is less than 5% or 95% confidence of an increase (Figure 3,
upper arrow). The lookup table in Figure 3 illustrates that low CTC
numbers result in a large uncertainty when a change in the true
average CTC number present in a patient is determined.
Changes in CTCs that Correlate with Survival
Four different criteria for CTC reduction were evaluated. We
tested a static cutoff, a confidence of reduction, a proportional reduc-
tion, and an absolute reduction. The boundaries for each criterion
when applied to the CTC definition are shown in Figure 4. The
figure shows the CTC number at baseline and first follow-up of
164 of 296 (65%) patients with unfavorable CTCs at baseline. The
static cutoff for unfavorable CTCs is 5 CTCs; the 99.9% probability
for CTC reduction was based on the Poisson model, the minimum
relative reduction was set at five-fold, and the minimum absolute
reduction was set at 13 CTCs. Using these specific values in each
approach resulted in a dichotomization that had 59% of the patients
in the unfavorable group, thus the relative group sizes for each criterion
remained constant.
For illustration purposes, two arrows are shown in Figure 4 to ex-
emplify the implications of applying these criteria. Arrow 1 is a pa-
tient that started with 11 CTCs, which reduced to 2 CTCs at first
follow-up. According to static CTC cutoff and relative CTC reduction,
this patient has a favorable prognosis, but using the 99.9% CTC re-
duction confidence or the absolute CTC decrease, this patient has an
Figure 1. Kaplan-Meier plots for OS of metastatic breast and pros-
tate cancer patients from the first blood draw after initiation of a line
of therapy. Log-rank P between patients with 0 versus 1 to 4 CTCs
was P = .044; 1 to 4 CTCs versus 5 to 24 CTCs, P = .002; and 5 to
24 CTCs versus ≥25 CTCs, P = .003.
Figure 2. Smoothed spline fits on the number of CTCs for patients that survived 1 to 6, 6 to 12, 12 to 24, and 24 to 36 months after
initiation of therapy. (A) Patients with unfavorable CTCs before initiation of therapy. (B) Patients with favorable CTCs before initiation of
therapy. Number of patients in each group are shown in parenthesis.
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unfavorable prognosis. The exact opposite case is indicated by arrow 2,
where a patient had 39 CTCs at baseline and 9 CTCs at first follow-up.
Applying the different methods for expression of CTC change in
patients with unfavorable CTCs at baseline (≥5 CTCs), we deter-
mined OS. The static cutoff predicted the largest difference in OS with
an HR of 2.1 (95% confidence interval (CI) = 1.4–3.2; P < .001) for
patients that converted from ≥5 CTCs to <5 CTCs. The relative
reduction of five-fold had an HR of 1.4 (95% CI = 1.0–2.1; P =
.06). Absolute reduction by ≥13 CTCs had an HR of 0.7 (95%
CI = 0.5–1.0; P = .06). Confidence of reduction of at least 99.9%
resulted in an HR of 0.7 (95% CI = 0.5–1.1, P = .12). The true con-
centration of CTCs was reduced in the majority of patients; confidence
of reduction was at least 50% for 74% of patients and at least 95%
for 56% of patients. Only when we set the threshold to 99.9%,
59% of patients were in the poor prognosis group.
Applying Criteria for CTC Change to Multiple Time Points
To create clear-cut rules for deciding whether or not a certain ther-
apy is working, survival of the group of unfavorable patients at baseline
was assessed for two subsequent follow-up measurements: the first
between 2 and 5 weeks and the second between 6 and 8 weeks after
initiation of therapy. Figures 1 and 2 show that it is important to treat
patients until the number of CTC becomes zero. One of 205 healthy
controls had one CTC (0.5%). To include the maximum number
of patients possible, the cutoff for unfavorable was set to ≥2 CTCs.
Kaplan-Meier survival curves were generated by assigning all patients
with ≥2 CTCs at baseline to one of five groups: 1) patients who
changed to favorable (<2 CTCs) at first follow-up (green line), 2)
patients who stayed unfavorable at first follow-up but changed to
favorable at second follow-up (cyan line), 3–5) patients who stayed
unfavorable at first and second follow-ups but 3) did not show a
95% significant rise in the number of CTCs (blue line), 4) had no sig-
nificant rise at first follow-up but a significant rise at second follow-up
(magenta line), and 5) had a significant rise at first follow-up (red
line). A 95% significant rise is approximately a 1.5-fold rise for
patients with ≥20 CTCs at baseline (Figure 3). Median survival for
groups 1 to 5 was 20.4, 17.9, 10.1, 5.1, and 5.0 months, respectively.
Log-rank P for comparison between the survival curves of patients of
groups 1 and 2 and between groups 4 and 5 were P > .8; groups 2 and
3 had P = .07. Comparison of groups 3 to 5 (group 5 is closer to
group 3 than to group 4) resulted in P = .17.
Discussion
Evidence that CTCs are an independent prognostic and predictive
biomarker for patients with metastatic carcinomas is increasing [2–
10,16–21]. Whether an early switch of treatment based on persis-
tence of CTC after the first cycle of therapy can prolong survival is
still being investigated in ongoing clinical studies (SWOG 0500—
NCT00382018). A difficulty that arises in applying the results of a
CTC assay to evaluate therapy response is the low number of CTCs
that are usually found in patients. Using the CellSearch system that
has been validated for CTC enumeration, patients are divided into
the following two groups: those with favorable CTCs (<5 CTCs/
7.5 ml of blood) and those with unfavorable CTCs (≥5 CTCs/
7.5 ml of blood). Examination of patient survival as a function of
the number of CTCs, however, clearly shows a significant correlation
between the CTC load and survival prospects as illustrated for breast
and prostate cancer patients in Figure 1. CTCs of metastatic breast
and prostate cancer patients were combined for this analysis to illus-
trate that an interpretation of CTC results can be made regardless of
origin of the disease or treatment.
Figure 3. Lookup table for the probability of a true reduction in CTC
count between two measurements. A true reduction occurs when
the true average present in a patient at the time of the second
measurement is lower than the true average at the time of the
first measurement.
Figure 4. Conversion from unfavorable to favorable CTCs using
the classic CTC definition of 296 metastatic breast and prostate
cancer patients. Four different criteria of assessing a CTC reduc-
tion are indicated with different lines. Arrows indicate patients
described in more detail in the text. BL, CTCs at baseline; FU1, CTCs
at first follow-up.
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Elimination of all CTCs clearly is the most desired outcome; the
time needed for a CTC reduction may, however, vary (Figure 2),
and it is of importance to have the proper tools to evaluate changes
in CTC numbers. Using Poisson statistics, a measure was given of
the confidence that two CTC measurements represent a true change
in the underlying average number of CTCs found in patients. A
lookup table (Figure 3) was created to assist physicians in determining
whether or not a change in CTCs is significant. For 56% of patients
in our data set, the observed reduction is significant with at least 95%
confidence. However, this reduction does not result in an improvement
of OS unless the absolute number of CTCs is reduced below 5 and
preferably approaches 0. We attribute this inconsequential reduction
to the cytotoxic chemotherapy, which kills cells in most patients but
probably does not target all malignant cells in those patients with short
survival. This means that CTCs that were found after therapy initia-
tion represent resistance to the current therapy. Characterization of
treatment targets on these CTCs may suggest an alternative, potentially
more effective therapy. A therapy that eliminates only a specific tumor
cell type provides an evolutionary advantage to the therapy-resistant
cell types. This may explain the brief decline in CTC count in patients
with survival of 6 to 12 months (Figure 2A).
Figure 2 further shows that a period of 10 to 12 weeks may be
needed before definitive conclusions can be drawn, whether a count
is going to zero. Figure 5 further confirms this conclusion, in which
only patients with multiple CTC measurements over a period of
3 months are included. It can be seen that patients who remain un-
favorable at first follow-up may improve at second follow-up, which
is reflected in their survival chances. Patients who have a rise in num-
ber of CTCs with at least 95% confidence deteriorate rapidly. The
therapeutic regimen of the majority of these patients included chemo-
therapy, and the rate of CTC decline may be dependent on the type
of therapy. Figure 2B shows that also for those patients with <5 CTCs
at baseline a strong upward trend is an indicator for poor prognosis,
even though the majority of patients with 6- to 12-month survival
have fewer than the clinically used cutoff of 5 CTCs after 12 weeks.
It is unknown whether these patients have a subtype of cancer, which
sheds fewer CTCs into the blood, or whether they rapidly deteriorated
after the last follow-up measurement.
To determine the best definition of a change in CTC count,
several reduction criteria were tested. Four criteria were used to
measure a reduction using modeled confidence of reduction, static,
absolute, and proportional cutoffs. For patients who started with five
or more CTCs, a count below a static cutoff after 6 to 8 weeks of
therapy remains the best indicator of treatment success. Combined
with Figure 1, we can again conclude that treatment should focus on
getting the number of CTCs to zero.
We conclude that 1) the aim of treatment should be the elimina-
tion of all CTCs, 2) while reduction to zero CTC can be seen after
4 to 6 weeks, to reach this aim, 10 to 12 weeks of therapy may be
needed for some patients, and 3) if the number does not decrease
within this time span, treatment is not effective.
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Table W1. Patient Characteristics.
Breast Prostate
N 111 185
Age 58 (27–86) 69 (49–92)
OS 16.1 (1.5–48.6) 16.9 (1.9–38.7)
Progression-free survival 5.5 (0.7–45.2) 5.0 (0.6–34.5)
Follow-up of censored patients 20.7 (5.5–48.6; n = 47) 25.9 (2.4–38.9; n = 67)
Therapy type (1/2/3)* 57.8%/5.5%/36.7% 8.2%/91.8%/0%
Therapy line (1/2/3+) 43.2%/15.3%/41.4% 67.0%/16.2%/16.8%
Bone metastases (yes/no) 90.6%/9.4% 87.4%/12.6%
Prostate-specific antigen (ng/ml) N/A† 128 (1.9–17,800)
Lactate dehydrogenase (IU/ml) N/A 236 (4.7–2364; n = 139)
Alkaline phosphatase (IU/ml) N/A 126 (3.29–1558; n = 179)
Hemoglobin (g/dl) N/A 12.4 (8.2–15.7; n = 182)
Albumin (g/dl) N/A 3.8 (2.1–41; n = 179)
Mucin glycoprotein, CA15.3 169.5 (0.9–19,315; n = 22) N/A
Milk mucin antigen, CA27.29 96 (9.9–23,204; n = 65) N/A
Carcinoembryonic antigen 8.2 (0.5–3920; n = 38) N/A
CTCs 6 (0–10,194) 7 (0–5925)
*Therapy types: 1 = chemo + other; 2 = chemo and hormone + other; 3 = hormone + other.
†Not applicable.
